2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

Core Insights - Biotech stocks present significant growth opportunities due to ongoing research and potential breakthroughs in treatments [1] - Wall Street identifies two biotech candidates with projected gains exceeding 80% and 200% in the next 12 months [2] Company Summaries Viking Therapeutics - Viking Therapeutics (VKTX) experienced a surge in stock price following positive phase 2 trial results for its weight loss drug VK2735, but has since returned to pre-announcement levels [4] - The company is advancing VK2735 in both injectable and pill forms, with high demand for weight loss drugs, indicating potential for future growth [5] - Viking is set to begin phase 3 trials for the injectable version in Q2 and expects phase 2 data for the pill version in the second half of the year, with the weight loss drug market projected to reach $100 billion [6] - Wall Street forecasts a 240% increase in Viking's stock price, contingent on trial outcomes [7] CRISPR Therapeutics - CRISPR Therapeutics (CRSP) saw its stock rise leading up to the approval of its first product, Casgevy, but has since declined as investors locked in gains [8] - The company is positioned for potential growth as Casgevy requires a longer rollout process, with expectations for significant increases in new patient initiations this year [10] - Positive phase 1 data for a gene-editing candidate targeting high cholesterol has been reported, with further updates expected on candidates for lipoprotein(a), oncology, and autoimmune diseases [11][12] - Wall Street anticipates an 84% gain for CRISPR Therapeutics, making it a potential buying opportunity for growth investors [12]